Skip to main content

MyMD Pharmaceuticals, Akers Biosciences Merging to Form Baltimore-Based Company

A merger of two medical device companies is bringing about a new Baltimore-based company that will be listed on the Nasdaq. MyMD Pharmaceuticals, Inc. has entered into a deal to merge with Akers Biosciences, Inc. to form a combined company focused on developing the drug candidates in MyMD Pharmaceuticals’ pipeline that use immunotherapy to treat autoimmune and age-related diseases. Dr. Adam Kaplin, an assistant professor at the The Johns Hopkins University School of Medicine in Baltimore, will become chief scientific officer of the company, according to Technical.ly.


Read More